MoonLake Immunotherapeutics
MLTXNasdaq
$19.68
↑ +3.5%Jul 17 close · end-of-day
Price
1Y↓ -62.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.4B
Enterprise Value
$1.1B
P/E
—
P/S
—
P/B
5.5
EV/EBITDA
—
PEG
—
FCF Yield
-16.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$257.1M
Free Cash Flow (TTM)
-$224.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-101.2%
ROIC
—
Debt / Equity
0.4
Net Cash
$258.9M
Return 1Y
-63.7%
Company profile
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, or ankylosing spondylitis.
- CEO
- Jorge Santos da Silva
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2
- Website
- moonlaketx.com
Management & directors
- Reich KristianChief Scientific Officer
- Santos Da Silva JorgeChief Executive Officer
- Bodenstedt MatthiasChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
MLTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.98↑ +55.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.6M | -$65.1M | -$54.1M | -$143.1M | -$244.8M |
| Net income | -$4.5M | -$50.0M | -$36.0M | -$118.9M | -$227.3M |
| Diluted EPS | — | -$1.70 | -$0.73 | -$1.89 | -$3.53 |
| Operating cash flow | -$611,071.00 | -$55.9M | -$42.8M | -$116.6M | -$196.0M |
| Free cash flow | — | -$55.9M | -$43.1M | -$117.1M | -$196.0M |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$30.6M | -$43.1M | -$49.6M | -$47.5M | -$60.7M | -$71.4M | -$65.2M | -$70.0M |
| Net income | -$24.3M | -$35.4M | -$45.6M | -$39.9M | -$55.2M | -$69.7M | -$62.4M | -$69.7M |
| Diluted EPS | -$0.39 | -$0.56 | -$0.72 | -$0.63 | -$0.87 | -$1.10 | -$0.93 | -$0.98 |
| Operating cash flow | -$27.9M | -$25.3M | -$48.5M | -$38.1M | -$54.5M | -$44.5M | -$58.8M | -$66.3M |
| Free cash flow | -$27.9M | -$25.4M | -$48.6M | -$38.2M | -$54.5M | -$44.5M | -$58.8M | -$66.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 25, 2026
Jun 24, 2026
- 26d agoExchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Easing US-Iran Tensionsfinance.yahoo.com
- 26d agoMLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Developmentstocktwits.com
- 26d agoMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offeringfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Reich Kristian· Chief Scientific Officer | Sale | 16,105 | $20.01 | $322,261.05 | filing |
| 2026-07-10 | Santos da Silva Jorge· Chief Executive Officer | Sale | 68,289 | $20.02 | $1.4M | filing |
| 2026-07-09 | Santos da Silva Jorge· Chief Executive Officer | Sale | 33,936 | $20.01 | $679,059.36 | filing |
| 2026-07-01 | Santos da Silva Jorge· Chief Executive Officer | Sale | 47,775 | $20.03 | $956,933.25 | filing |
| 2026-06-22 | Bodenstedt Matthias· Chief Financial Officer | Sale | 39,120 | $22.04 | $862,204.80 | filing |
| 2026-06-18 | Bodenstedt Matthias· Chief Financial Officer | Sale | 2,794 | $19.60 | $54,762.40 | filing |
| 2026-06-17 | Reich Kristian· Chief Scientific Officer | Sale | 50,000 | $19.43 | $971,500.00 | filing |
| 2026-06-17 | Bodenstedt Matthias· Chief Financial Officer | Sale | 15,082 | $19.68 | $296,813.76 | filing |
| 2026-06-16 | Reich Kristian· Chief Scientific Officer | Sale | 50,000 | $18.70 | $935,000.00 | filing |
| 2026-06-15 | Reich Kristian· Chief Scientific Officer | Sale | 50,000 | $18.89 | $944,500.00 | filing |
| 2026-05-11 | Bodenstedt Matthias· Chief Financial Officer | Sale | 13,653 | $20.02 | $273,333.06 | filing |
| 2026-04-14 | Bodenstedt Matthias· Chief Financial Officer | Sale | 2,426 | $19.56 | $47,452.56 | filing |
| 2026-04-13 | Santos da Silva Jorge· Chief Executive Officer | Sale | 51,873 | $18.23 | $945,644.79 | filing |
| 2026-04-10 | Santos da Silva Jorge· Chief Executive Officer | Sale | 98,127 | $18.41 | $1.8M | filing |
| 2026-04-10 | Bodenstedt Matthias· Chief Financial Officer | Sale | 1,925 | $19.51 | $37,556.75 | filing |
| 2026-04-09 | Bodenstedt Matthias· Chief Financial Officer | Sale | 85,870 | $18.94 | $1.6M | filing |
| 2026-03-31 | BVF PARTNERS L P/IL | Sale | 1,932,354 | $16.79 | $32.4M | filing |
| 2026-03-31 | BVF PARTNERS L P/IL | Sale | 1,569,116 | $16.79 | $26.3M | filing |
| 2026-03-31 | BVF PARTNERS L P/IL | Sale | 248,530 | $16.79 | $4.2M | filing |
| 2026-01-07 | Bodenstedt Matthias· Chief Financial Officer | Award | 354,296 | $0.00 | $0.00 | filing |
| 2025-12-19 | Bodenstedt Matthias· Chief Financial Officer | C | 294,473 | — | — | filing |
| 2025-12-19 | Bodenstedt Matthias· Chief Financial Officer | D | 294,473 | — | — | filing |
| 2025-12-19 | Reich Kristian· Chief Scientific Officer | C | 35,389 | — | — | filing |
| 2025-12-19 | Reich Kristian· Chief Scientific Officer | D | 35,389 | — | — | filing |
| 2025-12-19 | Santos da Silva Jorge· Chief Executive Officer | C | 196,316 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.